St. Louis, Missouri, United States of America
  • Surgical Downstaging in an Open-Label Phase II Trial of Denosumab in Patients with Giant Cell Tumor of Bone
    with P. Rutkowski, S. Ferrari, R. J. Grimer, P. D. Stalley, S. P. D. Dijkstra, A. Pienkowski, G. Vaz, J. S. Wunder, L. L. Seeger, A. Feng, and B. A. Bach
    © 2015, The Author.Background: Surgical resection with curative intent for giant cell tumor of bone may be associated with severe morbidity. This interim analysis evaluated reduction in surgical invasiveness after denosumab treatment in patients with resectable GCTB. Methods: Patients with primary or recurrent GCTB, for whom the initially planned surgery was associated with functional compromise or morbidity, received denosumab 120 mg subcutaneously every 4 weeks. Planned and actual GCTB-related…Read more